News

Longitudinal imaging of Tau aggregates in vivo by two-photon imaging available in reMYND’s Tau.P301S model

06-03-2015
Two-photon imaging allows tracking the formation of Tau aggregates  in the same brain-region of a live animal over the course of time. This makes it possible to study the effects of treatment longitudinally in vivo.

Transgenic mouse model of combined Abeta and tau pathology

17-12-2014
The interplay of Abeta and Tau is considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease.

Robust LTP measurements in Tau models

12-11-2014
Long term potentiation (LTP), a reflection of dendritic spine density and synaptic plasticity, is gaining importance as a functional ex-vivo or even in-vivo read-out related to learning and memory.

LTP measurements available through reMYND

11-08-2014
reMYND now offers Long Term Potentiation (LTP) measurements to allow clients to assess the effect of their experimental Alzheimer treatment.

reMYND’s novel diabetes treatment prevents – and even reverses – disease progression in pre-clinical diabetes models

05-05-2014
Press release | reMYND NV announced today that its experimental diabetes drug ReS39 has demonstrated a strong disease modifying effect in mice, in which the insulin producing capacity of β-cells is preserved - possibly even restored– in a durable way through a novel mechanism of action.

Pages